Cytokinetics Announces Four Upcoming Presentations at the European Society Of Cardiology Heart Failure 2025 Congress
Cytokinetics (NASDAQ: CYTK) has announced four upcoming presentations at the European Society of Cardiology Heart Failure 2025 Congress in Belgrade, Serbia (May 17-20, 2025). The presentations include three Late Breaking Science sessions and one ePoster presentation, focusing on the company's cardiovascular treatments.
Key presentations will cover: 1) Efficacy and safety of Aficamten in patients with obstructive hypertrophic cardiomyopathy, 2) SEQUOIA-HCM study results analyzing Aficamten treatment across geographical regions, 3) Exploratory analysis of Omecamtiv Mecarbil in the GALACTIC-HF trial, and 4) An ePoster on cardiovascular outcomes in non-obstructive hypertrophic cardiomyopathy patients.
Cytokinetics (NASDAQ: CYTK) ha annunciato quattro presentazioni in programma al Congresso 2025 della European Society of Cardiology Heart Failure che si terrà a Belgrado, Serbia (17-20 maggio 2025). Le presentazioni includono tre sessioni di Late Breaking Science e una presentazione ePoster, focalizzate sui trattamenti cardiovascolari dell'azienda.
Le presentazioni principali tratteranno: 1) Efficacia e sicurezza di Aficamten nei pazienti con cardiomiopatia ipertrofica ostruttiva, 2) Risultati dello studio SEQUOIA-HCM che analizza il trattamento con Aficamten in diverse regioni geografiche, 3) Analisi esplorativa di Omecamtiv Mecarbil nello studio GALACTIC-HF, e 4) Un ePoster sugli esiti cardiovascolari nei pazienti con cardiomiopatia ipertrofica non ostruttiva.
Cytokinetics (NASDAQ: CYTK) ha anunciado cuatro presentaciones próximas en el Congreso 2025 de la Sociedad Europea de Cardiología sobre Insuficiencia Cardíaca en Belgrado, Serbia (del 17 al 20 de mayo de 2025). Las presentaciones incluyen tres sesiones de Late Breaking Science y una presentación ePoster, centradas en los tratamientos cardiovasculares de la compañía.
Las presentaciones clave cubrirán: 1) Eficacia y seguridad de Aficamten en pacientes con miocardiopatía hipertrófica obstructiva, 2) Resultados del estudio SEQUOIA-HCM que analiza el tratamiento con Aficamten en distintas regiones geográficas, 3) Análisis exploratorio de Omecamtiv Mecarbil en el ensayo GALACTIC-HF, y 4) Un ePoster sobre resultados cardiovasculares en pacientes con miocardiopatía hipertrófica no obstructiva.
Cytokinetics (NASDAQ: CYTK)는 2025년 5월 17일부터 20일까지 세르비아 베오그라드에서 열리는 유럽 심장학회 심부전 2025 학술대회에서 예정된 네 건의 발표를 발표했습니다. 발표는 세 개의 Late Breaking Science 세션과 한 개의 ePoster 발표로 구성되며, 회사의 심혈관 치료제에 중점을 둡니다.
주요 발표 내용은 다음과 같습니다: 1) 폐쇄성 비대성 심근병증 환자에서 Aficamten의 효능 및 안전성, 2) 지리적 지역별 Aficamten 치료를 분석한 SEQUOIA-HCM 연구 결과, 3) GALACTIC-HF 시험에서의 Omecamtiv Mecarbil 탐색적 분석, 4) 폐쇄성 비대성 심근병증이 아닌 환자의 심혈관 결과에 관한 ePoster 발표.
Cytokinetics (NASDAQ : CYTK) a annoncé quatre présentations à venir lors du Congrès 2025 de la Société Européenne de Cardiologie sur l'Insuffisance Cardiaque à Belgrade, Serbie (du 17 au 20 mai 2025). Les présentations comprennent trois sessions Late Breaking Science et une présentation ePoster, axées sur les traitements cardiovasculaires de l'entreprise.
Les présentations clés porteront sur : 1) L'efficacité et la sécurité de Aficamten chez les patients atteints de cardiomyopathie hypertrophique obstructive, 2) Les résultats de l'étude SEQUOIA-HCM analysant le traitement par Aficamten selon les régions géographiques, 3) Une analyse exploratoire de Omecamtiv Mecarbil dans l'essai GALACTIC-HF, et 4) Un ePoster sur les résultats cardiovasculaires chez les patients atteints de cardiomyopathie hypertrophique non obstructive.
Cytokinetics (NASDAQ: CYTK) hat vier bevorstehende Präsentationen auf dem European Society of Cardiology Heart Failure 2025 Kongress in Belgrad, Serbien (17.-20. Mai 2025), angekündigt. Die Präsentationen umfassen drei Late Breaking Science-Sitzungen und eine ePoster-Präsentation, die sich auf die kardiovaskulären Behandlungen des Unternehmens konzentrieren.
Die wichtigsten Präsentationen behandeln: 1) Wirksamkeit und Sicherheit von Aficamten bei Patienten mit obstruktiver hypertropher Kardiomyopathie, 2) Ergebnisse der SEQUOIA-HCM-Studie zur Analyse der Aficamten-Behandlung in verschiedenen geografischen Regionen, 3) Explorative Analyse von Omecamtiv Mecarbil in der GALACTIC-HF-Studie und 4) Ein ePoster zu kardiovaskulären Ergebnissen bei Patienten mit nicht-obstruktiver hypertropher Kardiomyopathie.
- None.
- None.
SOUTH SAN FRANCISCO, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced three Late Breaking Science presentations and one ePoster presentation at Heart Failure 2025, an International Congress of the European Society of Cardiology, taking place in Belgrade, Serbia from May 17, 2025 – May 20, 2025.
Late Breaking Science Presentations
Title: Efficacy and Safety of Aficamten in Patients with Obstructive Hypertrophic Cardiomyopathy and Mild Symptoms
Presenter: Iacopo Olivotto, M.D., Professor of Cardiology at the University of Florence, Head of Cardiology at Meyer Children's Hospital, Florence, Italy
Date: May 17, 2025
Topic: Chronic Heart Failure
Session Title: Late Breaking Science in Heart Failure, Cardiomyopathies, Pulmonary Hypertension and Valvular Heart Disease
Session Type: Late Breaking Science
Session Time: 4:00 - 5:00 PM CEST
Presentation Time: 4:20 PM CEST
Location: Room 1
Title: SEQUOIA-HCM: Effect of Aficamten Treatment on Patients with Hypertrophic Obstructive Cardiomyopathy by Geographical Region
Presenter: Caroline Coats, M.D., Ph.D., Lead Clinician, West of Scotland Inherited Cardiac Conditions Service, Honorary Senior Lecturer, School of Cardiovascular and Metabolic Health, University of Glasgow
Date: May 18, 2025
Topic: Chronic Heart Failure
Session Title: Hottest Trials and Trial Updates (2)
Session Type: Late Breaking Science
Session Time: 10:45 AM - 12:15 PM CEST
Presentation Time: 11:11 AM CEST
Location: Room 1
Title: The Effect of Omecamtiv Mecarbil on Outcomes Analyzed Using the Win Ratio: An Exploratory Analysis of GALACTIC-HF
Presenter: Kieran F. Docherty, Ph.D., Clinical Senior Lecturer in Heart Failure and Clinical Trials and Honorary Consultant Cardiologist, University of Glasgow
Date: May 19, 2025
Topic: Pharmacotherapy
Session Title: Clinical Trials Updates in Medical Therapy
Session Type: Late Breaking Science
Session Time: 1:45 PM - 2:45 PM CEST
Presentation Time: 2:25 PM CEST
Location: Room 1
ePoster Presentation
Title: Associations Between Age and Sex and Cardiovascular Outcomes in Patients with Non-Obstructive Hypertrophic Cardiomyopathy
Presenter: Paulos Gebrehiwet, Ph.D., M.S., Senior Manager, Health Economics and Outcomes Research, Cytokinetics
Date: May 17, 2025
Topic: Clinical
Session Title: ePosters in Myocardial Disease (2)
Session Type: ePosters
Session Time: 9:00 AM - 5:00 PM CEST
Presentation Time: 1:26 PM CEST
Location: ePosters Screen 14 - Research Gateway
About Cytokinetics
Cytokinetics is a specialty cardiovascular biopharmaceutical company, building on its over 25 years of pioneering scientific innovations in muscle biology to advance a pipeline of potential new medicines for patients suffering from diseases of cardiac muscle dysfunction. Cytokinetics is readying for potential regulatory approvals and commercialization of aficamten, a cardiac myosin inhibitor following positive results from SEQUOIA-HCM, the pivotal Phase 3 clinical trial in patients with obstructive hypertrophic cardiomyopathy (HCM). Aficamten is also being evaluated in additional clinical trials enrolling patients with obstructive and non-obstructive HCM. Cytokinetics is also developing omecamtiv mecarbil, a cardiac myosin activator, in patients with heart failure with severely reduced ejection fraction (HFrEF), CK-586, a cardiac myosin inhibitor with a mechanism of action distinct from aficamten, for the potential treatment of heart failure with preserved ejection fraction (HFpEF) and CK-089, a fast skeletal muscle troponin activator with potential therapeutic application to a specific type of muscular dystrophy and other conditions of impaired skeletal muscle function.
For additional information about Cytokinetics, visit www.cytokinetics.com and follow us on X, LinkedIn, Facebook and YouTube.
Forward-Looking Statements
This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the "Act"). Cytokinetics disclaims any intent or obligation to update these forward-looking statements and claims the protection of the Act's Safe Harbor for forward-looking statements. Examples of such statements include, but are not limited to, statements relating to any of our other clinical trials, statements relating to the potential benefits of omecamtiv mecarbil, aficamten, or any of our other drug candidates. Cytokinetics' research and development activities; the design, timing, results, significance and utility of preclinical and clinical results; and the properties and potential benefits of Cytokinetics' other drug candidates. Such statements are based on management's current expectations, but actual results may differ materially due to various risks and uncertainties, including, but not limited to, potential difficulties or delays in the development, testing, regulatory approvals for trial commencement, progression or product sale or manufacturing, or production of Cytokinetics' drug candidates that could slow or prevent clinical development or product approval; Cytokinetics' drug candidates may have adverse side effects or inadequate therapeutic efficacy; the FDA or foreign regulatory agencies may delay or limit Cytokinetics' ability to conduct clinical trials; Cytokinetics may be unable to obtain or maintain patent or trade secret protection for its intellectual property; standards of care may change, rendering Cytokinetics' drug candidates obsolete; and competitive products or alternative therapies may be developed by others for the treatment of indications Cytokinetics' drug candidates and potential drug candidates may target. For further information regarding these and other risks related to Cytokinetics' business, investors should consult Cytokinetics' filings with the Securities and Exchange Commission.
CYTOKINETICS® and the CYTOKINETICS and C-shaped logo are registered trademarks of Cytokinetics in the U.S. and certain other countries.
Contact:
Cytokinetics
Diane Weiser
Senior Vice President, Corporate Affairs
(415) 290-7757
FAQ
What will Cytokinetics (CYTK) present at the ESC Heart Failure 2025 Congress?
When and where is the ESC Heart Failure 2025 Congress where CYTK will present?
What are the key drugs that Cytokinetics will discuss at the ESC Heart Failure 2025 Congress?
Who are the presenters for Cytokinetics at the ESC Heart Failure 2025 Congress?
